1 Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
2 Department of Pediatrics, The University of Texas MD Anderson Cancer center, Houston, TX, USA.
Am J Alzheimers Dis Other Demen. 2018 Feb;33(1):55-63. doi: 10.1177/1533317517733037. Epub 2017 Oct 6.
Some studies showed that Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) conveys susceptibility to Alzheimer's disease (AD) in females only. However, the confounding effects of some risk factors for AD were omitted in these studies. The aim of this meta-analysis comprising 19 604 patients with AD and 26 333 controls was to reexamine the association between Val66Met and AD by conditioning the effects of age, sex, and/or apolipoprotein E ( APOE) ε4 status. In agreement with the previous meta-analysis, Val66Met was associated with AD in females without confounding adjustment (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.03-1.14; P = .003). Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57). This comprehensive meta-analysis with the largest sample size demonstrated no association could be observed between Val66Met and AD in general or by dividing samples based on sex or APOE ε4.
一些研究表明,脑源性神经营养因子(BDNF)的 Val66Met 多态性仅使女性易患阿尔茨海默病(AD)。然而,这些研究忽略了 AD 的一些危险因素的混杂作用。本荟萃分析纳入了 19604 名 AD 患者和 26333 名对照,旨在通过调节年龄、性别和/或载脂蛋白 E(APOE)ε4 状态的作用,重新检验 Val66Met 与 AD 之间的关联。与之前的荟萃分析一致,未经混杂调整时,Val66Met 与女性 AD 相关(比值比[OR],1.08;95%置信区间[CI],1.03-1.14;P =.003)。然而,在调整年龄和 APOE ε4 状态后,Val66Met 与女性 AD 无关(OR,1.02;95% CI,0.94-1.11;P =.57)。这项具有最大样本量的综合荟萃分析表明,总体或根据性别或 APOE ε4 对样本进行划分,均无法观察到 Val66Met 与 AD 之间存在关联。